Skip to content

Investigating the effectiveness of oral tablet based on the Cuscuta epithymum on endometrioma

The effectiveness of oral tablet based on the Cuscuta epithymum on the pelvic pain, the quality of life and the size of the ovarian cyst of patients with endometrioma

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220108053669N4
Enrollment
68
Registered
2024-01-14
Start date
2024-01-21
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrioma. Malignant neoplasm of endometrium

Interventions

Intervention 1: Intervention group: The VAS scale is also filled by the patient before the start of the treatment on all days of the period and three times during the day and night. The patient is giv

Sponsors

Mazandaran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Endometriosis with pelvic pain and ovarian cyst over 2 cm Absence of Müllerian fibrosis adenomyosis and myoma Not taking medication such as painkillers Consent

Exclusion criteria

Exclusion criteria: Patient dissatisfaction Occurrence of pregnancy Drug complication

Design outcomes

Primary

MeasureTime frame
The effect of drugs on patients pain. Timepoint: Monthly since intervention, two months. Method of measurement: VAS(Visual Analogue Scale).

Secondary

MeasureTime frame
Drug effect on ovarian cyst size of patient. Timepoint: Two month since the beginning of intervention. Method of measurement: sonography.;Drug effect on the quality of life of patients. Timepoint: Monthly since intervention, two month. Method of measurement: EHP-30 Questionnaire.;Drug effect on the amount of painkillers usage in patients. Timepoint: Monthly since intervention, two month. Method of measurement: asking from patients.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactnegar Abbasi Sarmadi

Mazandaran University of Medical Sciences

negar.asarmadi@gmail.com+98 912 643 6775

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026